Treatment of primary FSGS in adults (Q26828859)

language of work or name

1 reference

November 2012

1 reference

Journal of the American Society of Nephrology

published in

1 reference

volume

23

1 reference

issue

11

1 reference

page(s)

1769-76

1 reference

Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome

cites work

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Therapy of the idiopathic nephrotic syndrome with alternate day steroids

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: a 20-year renal biopsy study

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing?

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Changing incidence of glomerular diseases in adults

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Primary focal segmental glomerulosclerosis: clinical course and response to therapy

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

The racial prevalence of glomerular lesions in nephrotic adults

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Editorial: Focal glomerular sclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Société de Néphrologie

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Clinical trial of focal segmental glomerulosclerosis in children and young adults

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Direct effects of dexamethasone on human podocytes

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Treatment of primary focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Long-term outcome in children and adults with classic focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: a pilot study

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Pathologic classification of focal segmental glomerulosclerosis: a working proposal

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Pathologic classification of focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

The genetic basis of FSGS and steroid-resistant nephrosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Other immunosuppressive agents for focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Hereditary proteinuria syndromes and mechanisms of proteinuria

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Treatment of nephrotic syndrome with cyclosporin A. What remains in 1994?

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis--a multicenter study

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population--epidemiology and outcome

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Management of idiopathic nephrosis in adults, including steroid-resistant nephrosis.

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study.

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Serial Estimates of Serum Permeability Activity and Clinical Correlates in Patients with Native Kidney Focal Segmental Glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

The glomerular tip lesion: what does it really mean?

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Focal glomerulosclerosis: natural history and treatment. A report of 70 cases.

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Idiopathic adult focal segmental glomerulosclerosis: a clinicopathological study and response to steroid

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

NPHS2 variation in sporadic focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Recessive NPHS2 (Podocin) mutations are rare in adult-onset idiopathic focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis.

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021

Fractional excretion of high- and low-molecular weight proteins and outcome in primary focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1681%2FASN.2012040389

7 January 2021